Retatrutide
Retatrutide is an investigational once-weekly injectable peptide from Eli Lilly: a “triple agonist” that activates the GIP, GLP-1, and glucagon receptors at…
Hub →
Each compound below has its own hub: what it is, what the published research actually shows, its legal and sports status, and the vendors whose batches have publicly published third-party test results. Coverage grows as the index grows.
Retatrutide is an investigational once-weekly injectable peptide from Eli Lilly: a “triple agonist” that activates the GIP, GLP-1, and glucagon receptors at…
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide developed by Eli Lilly. Unlike most compounds in this index, it is an approved…
BPC-157 is a synthetic 15-amino-acid peptide fragment derived from a protective protein found in gastric juice. It is one of the most…
TB-500 is a synthetic peptide based on thymosin beta-4, a naturally occurring protein involved in cell migration and repair. Like BPC-157, its…
NAD+ (nicotinamide adenine dinucleotide) is not actually a peptide. It is a coenzyme central to cellular energy metabolism that happens to be…
Semaglutide is the GLP-1 receptor agonist peptide that started the modern weight-loss era, approved as Ozempic (type 2 diabetes), Wegovy (weight management),…
PeptideCensus does not conduct testing. Each hub summarizes the published record: peer-reviewed research where it exists, regulatory and WADA status, and batch results aggregated from independent laboratories (see our data sources). For reconstitution and dosing math on any compound, use the free peptide calculator; for who actually sells tested product, see the vendor rankings.